Literature DB >> 29108785

Semaphorin7A aggravates coxsackievirusB3-induced viral myocarditis by increasing α1β1-integrin macrophages and subsequent enhanced inflammatory response.

Xuejie Wu1, Yawen Meng1, Chao Wang1, Yan Yue1, Chunsheng Dong2, Sidong Xiong3.   

Abstract

Semaphorin7A (Sema7A) has been reported to play various roles in nerve axon growth, tumor suppression, and tissue remodeling, as well as regulation of intestinal inflammation diseases. Viral myocarditis (VMC) characterized by viral-myocardial-cell necrosis and inflammatory cell infiltration is a common clinical disease of the cardiovascular system. However, the role of Sema7A in coxsackievirus B3 (CVB3)-induced VMC has not been reported. In this study, we generated an acute VMC mouse model by CVB3 infection, and manipulated Sema7A expression by in vivo polyethyleneimine-mediated Sema7A down-regulation. Our results indicated that Sema7A was up-regulated in cardiomyocytes during VMC, and that Sema7A down-regulation following short hairpin RNA interference or mAb neutralization effectively protected mice from VMC. Additionally, reduced inflammatory responses were observed along with Sema7A down-regulation. Furthermore, adoptive transfer of α1β1-integrin macrophages exacerbated CVB3-induced myocarditis, suggesting the significance of α1β1-integrin macrophages in response to VMC. We observed that co-culture of neonatal myocardiocytes with macrophages increased the percentage of α1β1-integrin macrophages, while Sema7A neutralization reduced α1β1-integrin macrophages in heart tissue of VMC mice. These results demonstrated that Sema7A, as an inflammation regulator in CVB3-induced VMC, might interact with α1β1-integrin in macrophages to enhance the inflammatory response and aggravate disease severity. Our findings provided insight into the potential role of Sema7A as a therapeutic treatment for VMC.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CVB3; Sema7A; inflammation; viral myocarditis; α1β1 integrin

Mesh:

Substances:

Year:  2017        PMID: 29108785     DOI: 10.1016/j.yjmcc.2017.11.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  4 in total

Review 1.  Semaphorins as Potential Immune Therapeutic Targets for Cancer.

Authors:  Jun Jiang; Fang Zhang; Yi Wan; Ke Fang; Ze-Dong Yan; Xin-Ling Ren; Rui Zhang
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 2.  Dirty Jobs: Macrophages at the Heart of Cardiovascular Disease.

Authors:  Travis W Stevens; Fatimah K Khalaf; Sophia Soehnlen; Prajwal Hegde; Kyle Storm; Chandramohan Meenakshisundaram; Lance D Dworkin; Deepak Malhotra; Steven T Haller; David J Kennedy; Prabhatchandra Dube
Journal:  Biomedicines       Date:  2022-07-02

3.  Involvement of VCP/UFD1/Nucleolin in the viral entry of Enterovirus A species.

Authors:  Jingjing Yan; Meng Wang; Min Wang; Ying Dun; Liuyao Zhu; Zhigang Yi; Shuye Zhang
Journal:  Virus Res       Date:  2020-04-11       Impact factor: 3.303

4.  Comprehensive analysis of neuronal guidance cue expression regulation during monocyte-to-macrophage differentiation reveals post-transcriptional regulation of semaphorin7A by the RNA-binding protein quaking.

Authors:  Huayu Zhang; Jurriën Prins; Dianne Vreeken; Barend W Florijn; Ruben G de Bruin; Oscar Rj van Hengel; Mieke F van Essen; Jacques Mgj Duijs; Hilde Van Esch; Eric P van der Veer; Anton Jan van Zonneveld; Janine M van Gils
Journal:  Innate Immun       Date:  2020-11-26       Impact factor: 2.680

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.